Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Alzinova

0.82 SEK-3.18 %4/9 17:29
Less than 1K followers

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-3.18 %
-24.91 %
+87.05 %
+40.44 %
-0.72 %
-43.63 %
-67.22 %
-85.98 %
-88.52 %

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.

Read more
Market cap
166.77M SEK
Turnover
771.12K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
12/11
2026

Interim report Q3'26

25/2
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-08-24 10:02

DNB Carnegie Access: Alzinova: Diagnostics readout next, partner process delayed – Q2 review

Alzinova
Press release2026-08-20 13:24

Redeye: Alzinova (Q2 Review): Capitalizing on diagnostics opportunities

Alzinova
Regulatory press release2026-08-20 08:54

Correction: Alzinova publishes interim report for the period January - June 2026

Alzinova

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-08-20 07:45

Alzinova offentliggör delårsrapport för januari – juni 2026

Alzinova
Regulatory press release2026-08-20 07:45

Alzinova publishes interim report for the period January - June 2026

Alzinova
Press release2026-07-07 07:09

BioStock: BioVal™-analys av Alzinovas ALZ-101 – rNPV om 7,1 miljarder SEK

Alzinova
Press release2026-07-07 07:09

BioStock: BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B

Alzinova
Press release2026-06-24 17:37

DNB Carnegie Access: Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds

Alzinova
Regulatory press release2026-06-24 09:00

Alzinova tecknar avsiktsförklaring med Fujirebio avseende potentiell kommersialisering av blodbaserat diagnostiskt test för Alzheimers sjukdom

Alzinova
Regulatory press release2026-06-24 09:00

Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test

Alzinova
Regulatory press release2026-06-12 07:30

Teckningsoptioner av serie TO4 nyttjades till cirka 94,2 procent och Bolaget tillförs cirka 15,3 MSEK

Alzinova
Regulatory press release2026-06-12 07:30

Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million

Alzinova
Regulatory press release2026-06-08 16:48

Alzinova offentliggör preliminärt utfall av nyttjandet av teckningsoptioner av serie TO4

Alzinova
Regulatory press release2026-06-08 16:48

Alzinova announces preliminary outcome of the exercise of warrants of series TO4

Alzinova
Regulatory press release2026-06-03 08:30

Sista dag för handel med teckningsoptioner av serie TO4 i Alzinova är idag, den 3 juni 2026

Alzinova
Regulatory press release2026-06-03 08:30

The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026

Alzinova
Regulatory press release2026-05-26 16:16

Bulletin from the Annual General Meeting of Alzinova AB (publ)

Alzinova
Regulatory press release2026-05-26 16:16

Kommuniké från årsstämma i Alzinova AB (publ)

Alzinova
Regulatory press release2026-05-25 08:30

Teckningskursen för nyttjandet av teckningsoptioner av serie TO4 i Alzinova har fastställts till 0,32 SEK och nyttjandeperioden inleds idag

Alzinova
Regulatory press release2026-05-25 08:30

The subscription price for warrants of series TO4 in Alzinova has been determined to SEK 0.32 and the exercise period begins today

Alzinova